Ro65-6570

Ro65-6570 is a benzodiazepine derivative drug, which is a subtype-selective GABAA receptor partial agonist. It was developed by Hoffmann–La Roche in the 1980s. Ro65-6570 has anxiolytic effects and enhances the action of GABA, but with less sedative effects compared to older benzodiazepine drugs. It is used in scientific research.

Pharmacology

Ro65-6570 is a subtype-selective GABAA receptor partial agonist, which means it produces only a partial response at the receptor compared to a full agonist. It has a high affinity for the α2 and α3 subtypes of the GABAA receptor, which are thought to be involved in the anxiolytic effects of benzodiazepines.

History

Ro65-6570 was developed by Hoffmann–La Roche in the 1980s as part of their efforts to develop non-sedating anxiolytics. It was one of a number of benzodiazepine derivatives developed by the company during this period.

Research

Ro65-6570 has been used in scientific research to study the role of the α2 and α3 GABAA receptor subtypes in the anxiolytic effects of benzodiazepines. It has also been used to investigate the potential for subtype-selective GABAA receptor agonists to produce less sedation and dependence than traditional benzodiazepines.

See also

• Benzodiazepine
• GABAA receptor
• Anxiolytic
• Hoffmann–La Roche

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Ro65-6570